Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Clinicopathologic Conference, Inflammatory Myopathy and Myasthenia Gravis Assoc. with Thymoma
NEJM 369:764-773, Case 26-2013, 2013
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Thymoma in Patients with MG
Neurol 59:1844-1850, Evoli,A.,et al, 2002
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Intestinal Pseudo-Obstruction, Myasthenia Gravis, and Thymoma
Neurol 47:985-987, Anderson,N.E.,et al, 1996
Assoc of Myasthenia Gravis with Extrathymic Hodgkin's Lymphoma:Resol of Myasth Sympt Following Antineopl Therapy
Neurol 45:1019, Abrey,L.E.&Askanas,V., 1995
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Clinical Syndromes of Myasthenia in Infancy & Childhood
Arch Neurol 35:97, Fenichel,G.M., 1978
Cause of Weakness in Myasthenia Gravis
NEJM 294:722, Grob,D., 1976
Diseases of Muscles-Clinical Manifestations & Differential Diagnosis
The New Physic 263, 1967, Oct., Boshes,L., 1967
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Extrathymic Tumors in Patients With Myasthenia Gravis, A 35-Year Retrospective Study
The Neurologist 12:53-55, Wakata,N.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis
Arch Neurol 60:243-248, Kupersmith,M.J.,et al, 2003
Difference in Distribution of Muscle Weakness Between Myasthenia Gravis and the Lambert-Eaton Myasthenic Syndrome
JNNP 73:766-768, Wirtz,P.W.,et al, 2002
Transcervical Thymectomy for Myasthenia Gravis Achieves Results Comparable to Thymectomy by Sternotomy
Ann Thorac Surg 74:320-326,326-327, Shrager,J.B.,et al, 2002
Brain Stem Compression by a Giant Vertebrobasilar Aneurysm Mimicking Seronegative Myasthenia
JNNP 71:125-126, Frisby,J.,et al, 2001
Clinicopath Conf.,Myasthenia Gravis with Thymoma, Case 15-2000
NEJM 342:1508-1514, , 2000
Retrospective Analysis of the Use of Cyclosporine in Myasthenia Gravis
Neurol 55:448-450, Ciafaloni,E. et al, 2000
Late-Onset Myasthenia Graivs,A Changing Scene
Arch Neurol 56:25-27, Aarli,J.A., 1999
Neuroendocrine Lung Tumors and Disorders of the Neuromuscular Junction
Neurol 52:1490-1491, Burns,T.M.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
The Long-Term Clinical Outcome of Myasthenia Gravis in Patients with Thymoma
Neurol 51:1198-1200, Bril,V.,et al, 1998
Myasthenia Gravis and Alopecia Areata
Neurol 48:774-775, Kubota,A.K.,et al, 1997
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340, LeForestier,N.,et al, 1995
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Continuous Muscle Fiber Activity, Peripheral Neuropathy, and Thymoma
Ann Neurol 29:215-218, Garcia-Merino,A.,et al, 1991
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
The Natural Course of Myasthenia Gravis:A Long Term Follow Up Study
JNNP 52:1121-1127, Oosterhuis,H.J.G., 1989
Myasthenia Gravis & Myasthenic Syndromes
Ann Neurol 16:519-534, Engel,A.G., 1984
Radiologic Evaluation of the Mediastinum in Myasthenia Gravis
Neurol 33:534-539, Janssen,R.S.,et al, 1983
Beta-Adrenoreceptor Antagonists & Diplopia
Lancet 2:826-827, Weber,J.C.P., 1982
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981